Arcutis Biotherapeutics, Inc. Announces the Publication of 14 Consensus Statements from the Genital Psoriasis Wellness Consortium

Published: 2025-05-15 10:35:29 ET ARQT

Published on 05/15/2025 at 10:35

Arcutis Biotherapeutics, Inc. announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients in the Journal of the European Academy of Dermatology and Venereology (JEADV) Clinical Practice. The consensus statements are aimed at providing expert, multidisciplinary guidance in three key areas: (1) physical diagnosis and patient conversations, (2) impact on quality of life and interpersonal relationships, and (3) treatment decisions. "Despite affecting an estimated six million Americans, genital psoriasis is often underreported and undertreated due to the uniquely sensitive and private nature of the afflicted areas, and uncertainty for how to begin the conversation.

Relative to psoriasis in other areas of the body, genital psoriasis also has a greater impact on psychological well-being and quality of life, interpersonal relationships, intimacy, feelings of stigmatization, and rates of depression," said Jennifer C. Cather, MD, FAAD, Medical Director and Founder of Mindful Dermatology and Modern Research Associates in Dallas, Texas, Genital Psoriasis Consortium member, and manuscript author. "With the current lack of formal guidelines around genital psoriasis, the goal of convening the Consortium was to bridge the gaps in clinician-patient communication, develop tools and processes that aid in identification and diagnosis, and better-informed shared treatment decisions".